Co., Ltd., Osaka, Japan). The excitation wavelength and the emission wavelength was set at 365nm and 450nm, respectively. The percent inhibition relative to positive (no test compound)controls was calculated.
Cytotoxicity Test
The cytotoxic activity of FR191512 against MDCKcells was compared with that of zanamivir and ribavirin. Concentration of the test compound required for 50% inhibition of cell growth (CC50) was determined. The cytotoxicity was colorimetrically determined at 550nm (and 660 nm as a reference) according to MTT method8'9). DEC. 2000 Results
In Vitro Anti-influenza Activity
The in vitro anti-influenza virus activity of FR191512
was compared with that of ribavirin and zanamivir using plaque formation inhibition assay ( appeared to be about 20-fold more active than ribavirin (IC50 of 6.40jum) but was 3-fold less effective than zanamivir (IC50 of 0.10/iM). However, the IC80 of FR191512 was 0.92jim and the value was almost equal to that ofzanamivir (IC80 of 0.87 jiu).
In Vivo Activity
The protective efficacy of FR191512, ribavirin and zanamivir in a mouse model of respiratory tract infection with influenza A/PR/8/34 virus was examined (Fig. 1 ).
These compounds prolonged the survival of infected mice. sialidase and yeast a-glucosidase.
Cytotoxic Activity
As shown in Table 4 , the cytotoxic activity of FR191512 against MDCK cells was weaker than ribavirin. The selective index value (CC50/IC50 in plaque assay) of FR1915 12 was 60-fold higher than ribavirin.
Discussion
The in vitro and in vivo anti-influenza virus activities of FR191512 were evaluated and compared with those of other antiviral agents. FR191512 showed potent antiinfluenza virus activity in vitro using plaque formation inhibition assay. The activity ofFR191512 was more potent than ribavirin but was less effective than zanamivir in assessment of the IC50 value. However, the IC80 value of FR191512 was almost equal to that of zanamivir. The results of plaque assay suggest that FR191512 has a strong anti-influenza efficacy. Furthermore, FR191512 showed a potent protective efficacy in a murine model of respiratory tract infection with influenza virus. The in vivo efficacy of FR191512 nearly reflected in vitro anti-influenza virus activity. The structure of FR191512 was determined as a novel polyphenolic compound. There are some reports concerning anti-influenza viral activities of polyphenol compounds from plant leaf extracts10). In these reports, tea polyphenols have inhibited the viral sialidase weakly but have strongly inhibited infectivity of influenza virus to MDCKcells by blocking its adsorption and entry into the cells. These knowledge may correlate closely with the results that FR191512 has weak viral sialidase inhibition activity but its anti-influenza viral efficacies in vitro and in vivo are strong. In the present study, we have not ever examined the mechanism of action for FR1915 12 until now. However, FR191512 may show the same mechanism of action as these polyphenols in our estimation.
